Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 2/20 | 0.44 |
| ▸ | PITRM1 | Q5JRX3 | 2/20 | 0.44 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.44 |
| ▸ | FAP | Q12884 | 1/20 | 0.44 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.44 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.44 |
| ▸ | ARG1 | P05089 | 2/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1485387 | 1.00 | DPP4 (0.44) | DPP4PITRM1DPP9FAPDPP8 | |
| SCHEMBL2211371 | 1.00 | DPP4 (0.44) | DPP4PITRM1DPP9FAPDPP8 | |
| SCHEMBL23536 | 0.80 | ARG1 (0.49) | DPP4PITRM1DPP9FAPDPP8 | |
| SCHEMBL23535 | 0.80 | ARG1 (0.49) | DPP4PITRM1DPP9FAPDPP8 | |
| Hydrochloric Acid SCHEMBL905291 | 0.78 | ARG1 (0.47) | DPP4PITRM1DPP9FAPDPP8 | |
| Hydrochloric Acid SCHEMBL16393846 | 0.78 | ARG1 (0.47) | DPP4PITRM1DPP9FAPDPP8 | |
| Hydrochloric Acid SCHEMBL905290 | 0.78 | ARG1 (0.47) | DPP4PITRM1DPP9FAPDPP8 | |
| SCHEMBL6245228 | 0.76 | DPP4 (0.40) | DPP4PITRM1DPP9FAPDPP8 | |
| SCHEMBL15790686 | 0.76 | ARG1 (0.33) | ARG1 | |
| Hydrochloric Acid SCHEMBL15776241 | 0.74 | ARG1 (0.32) | ARG1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9670228-B2 | Benzoxazepin PI3K inhibitor compounds and methods of use | GENENTECH, INC. (US) | 2017-06-06 | — | — | US | disclosed |
| US-20170081341-A1 | BENZOXAZEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2017-03-23 | — | — | US | disclosed |
| US-9546178-B2 | Benzoxazepin PI3K inhibitor compounds and methods of use | GENENTECH, INC. (US) | 2017-01-17 | — | — | US | disclosed |
| US-20160052933-A1 | BENZOXAZEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH INC (US) | 2016-02-25 | — | — | US | disclosed |
| US-9198918-B2 | Benzoxazepin PI3K inhibitor compounds and methods of use | GENENTECH, INC. (US) | 2015-12-01 | — | — | US | disclosed |
| CN-104744491-A | Benzoxazepin Pi3k Inhibitor Compounds And Methods Of Use | HOFFMAN LA ROCHE AG | 2015-07-01 | — | — | CN | disclosed |
| EP-2448935-B1 | SUBSTITUTED 2-CARBOXAMIDE CYCLOAMINO UREAS | NOVARTIS AG (CH) | 2015-06-24 | — | — | EP | disclosed |
| CN-102762576-B | Benzoxazepine PI3K inhibitor compounds and methods of use | HOFFMANN LA ROCHE | 2015-04-22 | — | — | CN | disclosed |
| EP-2845592-A1 | Benzoxazepin PI3K inhibitor compounds and methods of use | F. Hoffmann-La Roche AG (CH) | 2015-03-11 | — | — | EP | disclosed |
| US-20140288047-A1 | BENZOXAZEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH INC (US) | 2014-09-25 | — | — | US | disclosed |
| EP-2483278-A1 | BENZOXAZEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | F. Hoffmann-La Roche AG (CH) | 2012-08-08 | — | — | EP | disclosed |
| EP-2448935-A1 | SUBSTITUTED 2-CARBOXAMIDE CYCLOAMINO UREAS | Novartis AG (CH) | 2012-05-09 | — | — | EP | disclosed |
| WO-2011036280-A1 | BENZOXAZEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-31 | — | — | WO | disclosed |
| US-20110076292-A1 | BENZOXAZEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-31 | — | — | US | disclosed |
| US-20110003818-A1 | Substituted 2-Carboxamide Cycloamino Ureas | NOVARTIS AG (CH) | 2011-01-06 | — | — | US | disclosed |
| WO-2011000905-A1 | SUBSTITUTED 2-CARBOXAMIDE CYCLOAMINO UREAS | NOVARTIS AG (CH) | 2011-01-06 | — | — | WO | disclosed |
| US-4636567-A | CNS DISORDERS | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1987-01-13 | — | — | US | disclosed |
| US-4610821-A | CENTRAL NERVOUS SYSTEM, THYROTROPIN RELEASING HORMONE | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1986-09-09 | — | — | US | disclosed |
| US-4564609-A | NERVOUS SYSTEM DISORDERS | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1986-01-14 | — | — | US | disclosed |
| EP-0123444-A1 | 4-Substituted-2-azetidinone compound, process of producing the compounds, and medicaments containing the compounds | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1984-10-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140288047-A1 | BENZOXAZEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | BMX, PIK3CA, PI4KA | DPP4 2923/4885PITRM1 2007/4885DPP9 4192/4885 |
| US-20160052933-A1 | BENZOXAZEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | BMX, PIK3CA, PI4KA | DPP4 2923/4885PITRM1 2007/4885DPP9 4192/4885 |
| US-20110076292-A1 | BENZOXAZEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | BMX, PIK3CA, PI4KA | DPP4 2923/4885PITRM1 2007/4885DPP9 4192/4885 |
| US-20110003818-A1 | Substituted 2-Carboxamide Cycloamino Ureas | UCK2, ULK3, ULK2 | DPP4 2345/4885PITRM1 1748/4885DPP9 2499/4885 |
| US-20170081341-A1 | BENZOXAZEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | BMX, PIK3CA, PI4KA | DPP4 2923/4885PITRM1 2007/4885DPP9 4192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.